½ÅÁõÈıº : ½ÃÀå ÀλçÀÌÆ®, ¿ªÇÐ, ½ÃÀå ¿¹Ãø(2034³â)
Nephrotic Syndrome - Market Insights, Epidemiology, and Market Forecast-2034
»óǰÄÚµå : 1425962
¸®¼­Ä¡»ç : DelveInsight Business Research LLP
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 286 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 7,950 £Ü 10,972,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 11,925 £Ü 16,458,000
PDF (2-3 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 15,900 £Ü 21,945,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 23,850 £Ü 32,917,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÅÁõÈıº ½ÃÀå ±Ô¸ð´Â 2022³â ÁÖ¿ä 7°³±¹¿¡¼­ ÃÑ 4¾ï 100¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ¿¹Ãø ±â°£ Áß »ó´çÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÁÖ¿ä 7°³±¹ Áß ¹Ì±¹ÀÌ 2022³â ¾à 50%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϸç 2022³â EU 4°³±¹°ú ¿µ±¹ÀÌ 1¾ï 3,700¸¸ ´Þ·¯¿¡ ´ÞÇϰí, CAGRÀÌ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´ ±¹°¡ Áß µ¶ÀÏÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ°í ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ°¡ ±× µÚ¸¦ ÀÌÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ºÆäÀÎÀº °°Àº ÇØ¿¡ °¡Àå ³·Àº ½ÃÀå Á¡À¯À²À» º¸¿´À¸¸ç, ÀϺ»¸¸ 2022³â Àüü ½ÅÁõÈıº ½ÃÀåÀÇ ¾à 16%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Á¶»ç ±â°£ Áß »ó´çÇÑ CAGR·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÅÁõÈıº Ä¡·áÁ¦ ½ÃÀåÀÇ Àüü ½ÃÀå ±Ô¸ð´Â »õ·Ó°í È¿°úÀûÀÎ Ä¡·á¹ýÀÇ µîÀåÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÅÁõÈıºÀº Àú¾ËºÎ¹ÎÇ÷ÁõÀ» À¯¹ßÇÏ´Â ´Ù·®ÀÇ ´Ü¹é´¢·Î Á¤ÀǵǴ ÀÓ»ó ÁõÈıºÀ¸·Î °íÁöÇ÷Áõ, ºÎÁ¾ ¹× ´Ù¾çÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÏ´Â ÀÓ»ó ÁõÈıºÀÔ´Ï´Ù. ½ÅÁõÈıºÀÌ Àå±âÈ­µÇ¸é °¨¿°, ¿µ¾ç½ÇÁ¶, ½ÉÇ÷°ü°è Áúȯ À§Çè Áõ°¡ µîÀÇ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ È¿°úÀûÀÎ Ä¡·á¿Í Á¾ÇÕÀûÀÎ °ü¸®¸¦ À§Çؼ­´Â Á¤È®ÇÑ ¿øÀÎÀ» ÆÄ¾ÇÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

½ÅÁõÈıºÀÇ Áø´Ü °úÁ¤¿¡´Â ÀÓ»ó Æò°¡, Ç÷û ¾ËºÎ¹Î ¹× ÁöÁú ³óµµ¸¦ Æò°¡Çϱâ À§ÇÑ Ç÷¾× °Ë»ç, ´Ü¹é´¢¸¦ °ËÃâÇϱâ À§ÇÑ ¼Òº¯ °Ë»ç, ÃÊÀ½ÆÄ °Ë»ç¿Í °°Àº ¿µ»ó Áø´ÜÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ ½ÅÀå »ý°ËÀ» ÅëÇØ ±Ùº»ÀûÀÎ ¿øÀÎÀ» ã¾Æ³»¾î Á¤º¸¿¡ ÀÔ°¢ÇÑ Ä¡·á¹ýÀ» ¼±ÅÃÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¾ÇÕÀûÀÎ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ º´ÀÇ ´µ¾Ó½º¸¦ ÃæºÐÈ÷ ÀÌÇØÇϰí Á¤È®ÇÑ Áø´Ü°ú ÀûÀýÇÑ °³ÀÔÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÅÁõÈıºÀÇ Ä¡·á´Â ±Ùº»ÀûÀÎ ¿øÀÎÀ» ÇØ°áÇϰí Ç÷¾Ð »ó½Â, ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡ »ó½Â, ºÎÁ¾ ¹× °¨¿°¿¡ ´ëÇÑ °¨¼ö¼ºÀ» ¿ÏÈ­Çϱâ À§ÇÑ Á¶Ä¡¸¦ ÃëÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. Ä¡·áÀû °³ÀÔÀº ÀϹÝÀûÀ¸·Î ¾à¹° Ä¡·á¿Í ½ÄÀÌ¿ä¹ýÀ¸·Î ±¸¼ºµË´Ï´Ù. ÀϺΠÇ×°íÇ÷¾ÐÁ¦, ƯÈ÷ ACE ¾ïÁ¦Á¦¿Í ARB´Â ½ÅÁõÈıº°ú °ü·ÃµÈ ½ÅÀå ÁúȯÀÇ ÁøÇàÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä 7°³±¹ÀÇ ½ÅÁõÈıº ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í ¿ªÇÐ, ȯÀÚ µ¿Çâ, »õ·Î¿î Ä¡·á¹ý, 2034³â±îÁöÀÇ ½ÃÀå ±Ô¸ð ¿¹Ãø ¹× ÀÇ·áÀÇ ¹ÌÃæÁ· ¿ä±¸ µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦2Àå ¸®Æ÷Æ®ÀÇ ¼­·Ð

Á¦3Àå ½ÅÁõÈıº ½ÃÀå °³¿ä

Á¦4Àå ½ÅÁõÈıºÀÇ ¿ªÇаú ½ÃÀå Á¶»ç ¹æ¹ý

Á¦5Àå ½ÅÁõÈıºÀÇ °³¿ä

Á¦6Àå ÁÖ¿ä À̺¥Æ®

Á¦7Àå ½ÅÁõÈıº : ÁúȯÀÇ ¹è°æ°ú °³¿ä

Á¦8Àå ¿ªÇаú ȯÀÚ ¼ö

Á¦9Àå ȯÀÚ µ¿Çâ

Á¦10Àå Ãâ½Ã ¾àÁ¦

Á¦11Àå ½Å±Ô Ä¡·á¹ý

Á¦12Àå ½ÅÁõÈıº : ÁÖ¿ä 7°³±¹ ½ÃÀå ºÐ¼®

Á¦13Àå KOL ºä

Á¦14Àå SWOT ºÐ¼®

Á¦15Àå ¹ÌÃæÁ· ¿ä±¸

Á¦16Àå ½ÃÀå Á¢±Ù°ú »óȯ

Á¦17Àå ºÎ·Ï

Á¦18Àå DelveInsight ¼­ºñ½º ³»¿ë

Á¦19Àå ¸éÃ¥»çÇ×

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Key Highlights:

DelveInsight's "Nephrotic Syndrome - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Nephrotic Syndrome market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Nephrotic Syndrome market size from 2020 to 2034. The report also covers current Nephrotic Syndrome treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

Study Period: 2020-2034

Disease Understanding and Treatment Algorithm

Nephrotic Syndrome Overview

Nephrotic syndrome is a clinical syndrome defined by massive proteinuria responsible for hypoalbuminemia, with resulting hyperlipidemia, edema, and various complications. Nephrotic syndrome may stem from diverse underlying factors, encompassing conditions like minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, specific medications, and more. Prolonged nephrotic syndrome can result in complications such as infections, malnutrition, and an elevated risk of cardiovascular disease. Consequently, accurately pinpointing the precise cause is imperative for effective treatment and comprehensive management.

From a pathological standpoint, nephrotic syndrome entails changes in the structure and function of the glomeruli, which are the small filtration units in the kidneys tasked with eliminating waste and surplus fluids from the blood. The key characteristics of nephrotic syndrome involve heightened permeability of the glomerular filtration barrier, leading to the excretion of proteins, notably albumin, in the urine.

Nephrotic Syndrome Diagnosis

The diagnostic process for nephrotic syndrome encompasses a clinical assessment, blood examinations to evaluate serum albumin and lipid concentrations, urine analyses to detect proteinuria and imaging modalities such as ultrasound. Additionally, a kidney biopsy may be undertaken to pinpoint the root cause, aiding in informed treatment choices. This comprehensive approach ensures a thorough understanding of the condition's nuances, facilitating precise diagnosis and tailored interventions.

Nephrotic Syndrome Treatment

The treatment of nephrotic syndrome involves addressing the fundamental cause and implementing measures to mitigate elevated blood pressure, elevated cholesterol levels, edema, and infection susceptibility. Therapeutic interventions typically comprise medications and dietary modifications. Certain antihypertensive drugs, specifically ACE inhibitors and ARBs, exhibit the potential to decelerate kidney diseases associated with nephrotic syndrome.

Nephrotic Syndrome Epidemiology

As the market is derived using the patient-based model, the Nephrotic Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Nephrotic Syndrome and Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

As per DelveInsight's estimations, the total diagnosed prevalent cases of Nephrotic Syndrome in the 7MM were approximately 786 thousand in 2022 and are projected to increase during the forecast period.

Nephrotic Syndrome Drug Chapters

The drug chapter segment of the Nephrotic Syndrome report encloses a detailed analysis of Nephrotic Syndrome marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Nephrotic Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

Atacicept: Vera Therapeutics

Atacicept developed by Vera Therapeutics, is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy and lupus nephritis.

Atrasentan: Chinook Therapeutics/ Novartis

Atrasentan is an oral potent and selective endothelin A (ETA) receptor antagonist, which works by inhibiting the ETA receptor activation of multiple renal cell types. This blockade reduces kidney inflammation and fibrosis, thus leading to reduced proteinuria in patients with chronic kidney disease.

Note: Detailed emerging therapies assessment will be provided in the final report of Nephrotic Syndrome.

Nephrotic Syndrome Market Outlook

Nephrotic syndrome is a collection of symptoms that signal impaired kidney function. These symptoms encompass proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other associated complications.

The management of nephrotic syndrome entails addressing underlying medical conditions contributing to its onset. Healthcare professionals may prescribe medications and dietary modifications to regulate symptoms and address complications associated with nephrotic syndrome. Currently, there are no authorized therapies specifically designed for treating nephrotic syndrome, and the predominant treatment strategies often involve off-label approaches. Corticosteroids like prednisone, cyclophosphamide, and cyclosporine are employed to induce remission in nephrotic syndrome. Diuretics are utilized to alleviate edema, while angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are employed to diminish proteinuria.

Progress in the treatment of nephrotic syndrome has transformed patient care, integrating lifestyle modifications, medications, and procedures. Emerging therapies, including monoclonal antibodies and antagonists targeting APRIL and BAFF, among others, hold the potential for improving patient outcomes. Continuous research and ongoing clinical trials are shaping a promising future for nephrotic syndrome treatment, providing optimism for a world with decreased morbidity and mortality.

The market for Nephrotic Syndrome is expected to experience positive growth with the approval of potential drugs like Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.

Nephrotic Syndrome Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Atacicept in the US is expected to be launched by 2027.

Further detailed analysis of emerging therapies drug uptake in the report…

Nephrotic Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Nephrotic Syndrome emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Nephrotic Syndrome evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Boston Children's Hospital, Ohio State University, Montefiore Medical Center, Hannover Medical School, Hannover, Hopital Robert-Debre, APHP, Paris, Istituto G. Gaslini, Genoa, Hospital Universitario Fundacion Jimenez Diaz, UCL Department of Renal Medicine, National Health Service, England, Fukushima Medical University, Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Japan, and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Nephrotic Syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

Nephrotic Syndrome Report Insights

Nephrotic Syndrome Report Key Strengths

Nephrotic Syndrome Report Assessment

Key Questions:

Market Insights

Epidemiology Insights

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

Reasons to Buy:

Frequently Asked Questions

1. What is the forecast period covered in the report?

2. Who are the key players in the Nephrotic Syndrome market?

3. How is the market size estimated in the forecast report?

4. What is the key driver of the Nephrotic Syndrome market?

5. What is the expected impact of emerging therapies or advancements in Nephrotic Syndrome treatment on the market?

6. Does the report provide insights into the competitive landscape of the market?

Table of Contents

1. Key Insights

2. Report Introduction

3. Nephrotic Syndrome Market Overview at a Glance

4. Epidemiology and Market Methodology of Nephrotic Syndrome

5. Executive Summary of Nephrotic Syndrome

6. Key Events

7. Nephrotic Syndrome: Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Emerging Therapies

12. Nephrotic Syndrome: Seven Major Market Analysis

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â